

Supplemental Table 1: Comparison of ^{18}F -DCFPyL PET/CT findings to conventional imaging

Number of scans (%)	CT	MR	$^{99\text{m}}\text{Tc}$ MDP Bone Scan	^{18}F -NaF PET/CT	^{18}F -Fluciclovine PET/CT
Congruent	7 (33)	13 (65)	16 (67)	10 (71)	8 (44)
Non-Congruent	14 (67)	7 (35)	8 (33)	4 (29)	10 (56)
Positive ^{18}F -DCFPyL PET	12	5	6	2	5
Negative ^{18}F -DCFPyL PET	1		1	1	1
Different findings	1	2	1	1	4

Supplemental Table 2: Impact of ^{18}F -DCFPyL PET/CT on Patient Management

Number of patients (% total patients)	Positive ^{18}F -DCFPyL PET				Negative ^{18}F - DCFPyL PET
	Total	Prostatectomy	Radiation therapy	Negative conventional imaging [†]	Total
Radiation with or without ADT	20 (28)	15 (21)	5 (7)	6 (8)	3 [‡] (4)
ADT	23 (32)	12 (17)	11 (15)	11 (15)	3 (4)
Surveillance	5 (7)	3 (4)	2 (3)	3 (4)	5 (7)
Other	13* (18)	5 (7)	8 (11)	6 (8)	

*Six patients with no documented follow up management plan yet. Three patients started ADT before the scan and continued afterwards. Three patients need additional work-up. One patient had ^{18}F -DCFPyL PET as a requirement to participate in a clinical trial.

[†]Eight patients had not had any documented conventional imaging.

[‡]Two patients with negative ^{18}F -DCFPyL PET scans received radiation therapy to prostate bed and pelvic lymph nodes. One patient who had negative ^{18}F -DCFPyL PET but prostate bed uptake on ^{18}F -Fluciclovine PET received radiation therapy.